SCHEMBL14140367

SCHEMBL14140367

CC(=O)NCCCNc1nccc(-c2ccnc(Nc3cccc(C)c3)n2)c1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 3/20 0.48
PIK3CA P42336 2/20 0.48
PIK3CG P48736 2/20 0.48
BCR P11274 2/20 0.48
PIK3CB P42338 1/20 0.48
SIRT5 Q9NXA8 1/20 0.47
CCNB2 O95067 1/20 0.47
CDK1 P06493 1/20 0.47
RET P07949 1/20 0.47
CCNB1 P14635 1/20 0.47
CCNB3 Q8WWL7 1/20 0.47
DYRK1A Q13627 1/20 0.46
SYK P43405 3/20 0.45
SRC P12931 2/20 0.45
CDK2 P24941 2/20 0.45
ZAP70 P43403 1/20 0.45
AURKA O14965 1/20 0.42
MAPK8 P45983 1/20 0.42
AURKB Q96GD4 1/20 0.42
EGFR P00533 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3605169 0.91 CDK2 (0.51) ABL1PIK3CAPIK3CGBCRPIK3CB
SCHEMBL3603519 0.90 SYK (0.49) ABL1BCRSIRT5CCNB2CDK1
SCHEMBL3607290 0.89 ABL1 (0.43) ABL1BCRSIRT5CDK1SYK
SCHEMBL3603517 0.88 ABL1 (0.41) ABL1PIK3CAPIK3CGBCRPIK3CB
SCHEMBL3609681 0.88 CDK2 (0.51) ABL1PIK3CAPIK3CGBCRPIK3CB
SCHEMBL13502999 0.84 TBK1 (0.51) ABL1PIK3CAPIK3CGBCRPIK3CB
SCHEMBL3604092 0.84 CDK1 (0.54) SIRT5CCNB2CDK1RETCCNB1
SCHEMBL3606836 0.82 SYK (0.47) ABL1PIK3CAPIK3CGBCRPIK3CB
SCHEMBL3602605 0.81 CDK2 (0.50) ABL1PIK3CAPIK3CGBCRPIK3CB
SCHEMBL3608990 0.81 MAPT (0.52) ABL1PIK3CAPIK3CGBCRPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008079933-A2 HETEROARYL-HETEROARYL COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER, INFLAMMATION AND VIRAL INFECTIONS NOVARTIS AG (CH) 2008-07-03 WO disclosed